Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Tyra Biosciences Receives IND for TYRA-300 in Bladder Cancer Trial
Details : TYRA-300 is an investigational, oral, FGFR3-selective inhibitor currently in development for the treatment of non-muscle invasive bladder cancer.
Product Name : TYRA-300
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 10, 2025
Lead Product(s) : TYRA-300
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Tyra Biosciences Receives IND Clearance for TYRA-300 in Pediatric Achondroplasia
Details : TYRA-300 is an investigational, oral, FGFR3-selective inhibitor currently in development for the treatment of cancer and skeletal dysplasias, including peidatric achondroplasia.
Product Name : TYRA-300
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 28, 2024
Lead Product(s) : TYRA-300
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TYRA-300
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Tyra Reports Proof-Of-Concept Data for TYRA-300 in Metastatic Cancer
Details : TYRA-300 is an investigational, oral, FGFR3-selective inhibitor currently in development for the treatment of cancer and skeletal dysplasias, including metastatic urothelial cancer.
Product Name : TYRA-300
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 24, 2024
Lead Product(s) : TYRA-300
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TYRA-300
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Tyra Biosciences Announces Proof-of-Concept Results for TYRA-300 in Hypochondroplasia
Details : TYRA-300 is an oral, potent FGFR3-selective tyrosine kinase inhibitor developed from compay's SNAP platform for treatment of hypochondroplasia and achondroplasia.
Product Name : TYRA-300
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 07, 2024
Lead Product(s) : TYRA-300
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TYRA-300
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : RA Capital Management
Deal Size : $200.0 million
Deal Type : Private Placement
Tyra Biosciences, Inc. Announces $200 Million Private Placement Financing
Details : The net proceeds will be used for the development of TYRA-300 an investigational, oral, FGFR3-selective inhibitor currently in development for the treatment of achondroplasia.
Product Name : TYRA-300
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 02, 2024
Lead Product(s) : TYRA-300
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : RA Capital Management
Deal Size : $200.0 million
Deal Type : Private Placement
Lead Product(s) : TYRA-300
Therapeutic Area : Genetic Disease
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Tyra Receives FDA Rare Pediatric Disease Designation for TYRA-300 in Achondroplasia
Details : TYRA-300 is an investigational, oral, FGFR3-selective inhibitor currently in development for the treatment of cancer and skeletal dysplasias, including achondroplasia.
Product Name : TYRA-300
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 02, 2024
Lead Product(s) : TYRA-300
Therapeutic Area : Genetic Disease
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Tyra Biosciences Doses First Patient with TYRA-200 and Provides Positive Updates on TYRA-300
Details : TYRA-200 is an oral, FGFR1/2/3 inhibitor with potency against activating FGFR2 gene alterations and resistance mutations, it is currently undergoing Phase 1 study for adults with advanced/metastatic intrahepatic cholangiocarcinoma and other advanced soli...
Product Name : TYRA-200
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 22, 2023
Lead Product(s) : TYRA-300
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Tyra Biosciences Expands Development of TYRA-300, an Oral FGFR3 Selective Agent, into Achondroplasia
Details : TYRA-300 is an investigational, oral, FGFR3-selective inhibitor currently in development for the treatment of cancer and skeletal dysplasias including achondroplasia.
Product Name : TYRA-300
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 03, 2023
Lead Product(s) : TYRA-300
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TYRA-300
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Tyra Biosciences Initiates SURF301 Phase 1/2 Clinical Study and Doses First Patient with TYRA-300
Details : TYRA-300 is an FGFR3 selective inhibitor for the treatment of metastatic urothelial carcinoma of the bladder and urinary tract,is developing initially in intrahepatic cholangiocarcinoma.
Product Name : TYRA-300
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 29, 2022
Lead Product(s) : TYRA-300
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TYRA-300
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TYRA-300 is an FGFR3-selective inhibitor designed to be agnostic to the gatekeeper mutation and has demonstrated less hyperphosphatemia mediated by FGFR1 inhibition than pan-FGFR inhibitors in preclinical models.
Product Name : TYRA-300
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 09, 2022
Lead Product(s) : TYRA-300
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable